The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 701–800 of 838
Management of Regional Nodal Melanoma
Angeles, C. V., & Wong, S. L. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.02.007 · Cited by 1
Nivolumab in Melanoma: An Overview of Medical Literature and Future Perspectives
Stucci, L. S., Todisco, A., Mandalà, M., & Tucci, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_11 · Cited by 1
Ipilimumab in Melanoma: An Evergreen Drug
Spagnolo, F., Tanda, E. T., & Mandalà, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_10 · Cited by 1
Kong, J. C. H., Flood, M. P., Ramsay, R. G., Warrier, S. K., & Heriot, A. G. (2021) · ANZ Journal of Surgery · doi:10.1111/ans.16485 · Cited by 1
Medical Treatment of Melanoma: Adjuvant and Neoadjuvant Therapies
Spagnolo, F., Tanda, E. T., Boutros, A., Cecchi, F., & Queirolo, P. (2020) · Updates in surgery/Updates in surgery series · doi:10.1007/978-3-030-45347-3_16 · Cited by 1
Patel, A. A., & Skitzki, J. J. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26746 · Cited by 1
Preoperative immune-therapy combination shows promise in skin cancer
(2022) · Nature · doi:10.1038/d41586-022-03152-2 · Cited by 1
Time may Heal All Wounds, but While It Does, Melanoma Marches on
Ollila, D. W., & Meyers, M. O. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07674-4 · Cited by 1
Applying adjuvant therapy for melanoma into clinical practice
Krishnan, T., Menzies, A. M., & Roberts‐Thomson, R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1841641 · Cited by 1
Single-Cell Manifold Preserving Feature Selection (SCMER)Preprint
Chen, K., Liang, S., Mohanty, V., Dou, J., Miao, Q., Huang, Y., Müftüoğlu, M., Ding, L., & Peng, W. (2020) · Research Square · doi:10.21203/rs.3.rs-119885/v1 · Cited by 1
Beitraege zur Systematik der Tribus Mesochorini Japans (Hym. Ichneumonidae)
Uchida, T. (1933) · Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) · Cited by 1
Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable MelanomaPreprint
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A., Chauvin, J.-M., Amatore, F., Stein, J. E., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2235839/v1 · Cited by 1
Synergy of HLA class I and II shapes the timing of antitumor immune responsePreprint
Papp, B. T., Fülöp, A. T., Balogh, G. M., Koncz, B., Spekhardt, D., & Manczinger, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.16.516740 · Cited by 1
Data from CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Kumar, A., Mohamed, E., Tong, S., Chen, K. Y., Mukherjee, J., Lim, Y., Wong, C. M., Boosalis, Z., Shai, A., Pieper, R. O., et al. (2023) · doi:10.1158/1078-0432.c.6531363.v1 · Cited by 1
Wang, G., Yoon, D., Patel, K., Nandi, A., Azar, T., Kim, J. J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5126088 · Cited by 1
Window-of-Opportunity Trials: The Road Forward in Soft Tissue Sarcoma and Beyond
Keung, E. Z.-Y., & Roland, C. L. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07193-2
Immune checkpoint modulation: Tenets and implications in glioblastoma
Nduom, E. K.-E., Lynes, J. P., Sánchez, V., Nwankwo, A., & Dominah, G. A. (2019) · Glioma · doi:10.4103/glioma.glioma_47_18
Checkpoint Inhibitors in the Treatment of Metastatic Melanoma
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_39-1
New developments in the perioperative treatment of melanomas with locoregional advancement
Rutkowski, P. L., Wysocki, W. M., Świtaj, T., & Jeziorski, A. (2019) · Nowotwory Journal of Oncology · doi:10.5603/njo.2019.0019
Schulz, G. B., & Black, P. C. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.019
van Akkooi, A. C. J., & Spillane, A. J. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08570-y
Management of Melanoma Patients with Positive Nodes
Lee, R. M., Delman, K. A., & Lowe, M. (2020) · Advances in Surgery · doi:10.1016/j.yasu.2020.03.001
Mahuron, K. M., Levine, L. S., & DAUD, A. I. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08672-7
Krijgsman, O., Kemper, K., Boshuizen, J., Vredevoogd, D. W., Rozeman, E. A., Molero, S. I., de Bruijn, B., Cornelissen‐Steijger, P., Shahrabi, A., Velasco‐Herrera, M. D. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.14.202408
Thiem, A. (2020) · Kompass Onkologie · doi:10.1159/000510458
エレーヌ・シクスー『内部』にあらわれる二元性について(研究発表要旨)
上田, 章. (2008) · フランス語フランス文学研究 · doi:10.20634/ellf.93.0_207
Adjuvante und neoadjuvante Therapie des metastasierenden Melanoms
Mohr, P. (2020) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-020-8241-y
Germain, C., Kaplon, H., & Dieu‐Nosjean, M. (2021) · médecine/sciences · doi:10.1051/medsci/2020276
Neoadjuvant and Adjuvant Therapies of Melanoma
Rutkowski, P. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_20
Neoadjuvant Therapy in Resectable Melanoma
Schlick, C. J. R., & Wayne, J. D. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.004
Challenges for NK cell-based therapies: What can we learn from lymph nodes?
Rethacker, L., Dulphy, N., & Caignard, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00002-3
Proteomic biomarker technology for cancer immunotherapy
Fankhauser, R. G., DePatie, N., Berryman, R., Lucero, O. M., & Kulkarni, R. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00007-3
Spatial mapping of the tumor immune microenvironment
Wu, Y.-C., Pagacz, J., Emery, S. C., Kron, S. J., & Lee, S. S.-Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00009-7
Three Cases of Anorectal Malignant Melanoma Treated with Laparoscopic Abdominoperineal Resection
Yoshida, S., Suzuki, N., Tomochika, S., Shindo, Y., Tokumitsu, Y., Iida, M., Takeda, S., Ioka, T., Hazama, S., Shirahama, T., et al. (2021) · 日本消化器外科学会雑誌 · doi:10.5833/jjgs.2020.0015
Evolution of Neoadjuvant Therapy in Melanoma
Fawaz, B., Rasic, G., & Sachs, T. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_9
Cusano, E., Wong, C., Taguedong, E., Vaska, M. M., Abedin, T., Nixon, N. A., Karim, S., Tang, P. A., Heng, D. Y. C., & Ezeife, D. A. (2021) · Current Oncology · doi:10.3390/curroncol28060412
Opinion editorial: "Creating a Cool Place for Business."
Mendel, S. (2002) · EngagedScholarship @ Cleveland State University (Cleveland State University)
Misticismo y Melancolía: Reforma de los cuidados de salud mental en la España moderna
Martínez, M. A. (2004) · Revista ROL de enfermería
Technicoeconomic analysis of purification buildings
Alipova, L. P., & Afonskaya, V. V. (1984) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
State-of-the-Art and Future Role of Molecular Biomarkers for Patient Selection
Jalanko, T., Roumiguié, M., & Black, P. C. (2022) · Springer eBooks · doi:10.1007/978-3-030-80546-3_8
Improving immunotherapy responses in gastrointestinal cancers
Chalabi, M. (2022) · doi:10.33540/904
Vernadou, A., Ferahta, N., Mederos, N., Ferraro, D. A., Dischl-Antonioni, I., Diciolla, A., Liapi, A., Mosimann, V., Latifyan, S., Aedo-Lopez, V., et al. (2020) · JMIG · doi:10.53738/revmed.2020.16.676-77.0072
When Is Surgery the Optimal Adjuvant Treatment?
Delman, K. A., & Wong, S. L. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2021.7577
Practical Management of Melanoma
Keung, E. Z.-Y., & Naylor, M. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-50593-6_15
Checkpoint Inhibitors in the Treatment of Metastatic Melanoma
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_39
Covelli, A. M., Min, H., McCready, D. R., Hong, N. J. L., Lipa, J. E., Petrella, T. M., & Wright, F. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-48363-0_16
Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
Keung, E. Z.-Y., Amaria, R. N., Sondak, V. K., Ross, M. I., Kirkwood, J. M., & Wargo, J. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_70-1
Self-citationImmunotherapy in Melanoma and Merkel Cell Cancer
Chow, M., Sangalang, E. A., Chow, C., & DAUD, A. I. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_67
The Role of Surgery in Managing Primary and Metastatic Melanoma
Rhodin, K. E., Baecher, K. M., Mehtsun, W. T., Lowe, M., Boland, G. M., & Beasley, G. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_36
Advanced HCC precision modeling reveals divergent responses to combinatorial immunotherapyPreprint
Liu, J., Cheng, L., El‐Mekkoussi, H., Lee, M., Jaffe, D. R., Gavin-Darby, K., Morgan, A. R., Manduchi, E., Schug, J., & Kaestner, K. H. (2022) · Research Square · doi:10.21203/rs.3.rs-1919053/v1
Diefenhardt, M., Fokas, E., & Rödel, C. M. (2022) · Strahlentherapie und Onkologie · doi:10.1007/s00066-022-01990-7
Kidman, J., Zemek, R. M., Principe, N., Corrêa, D., Sheikh, F., Fear, V. S., Forbes, C. A., Chopra, A., Boon, L., de Jong, E., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1613398/v1
Nie, R., Chen, F., Provencio, M., Wang, Y., van den Ende, T., van Laarhoven, H. W. M., Yuan, S., Pless, M., Hayoz, S., Zhou, Z., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4195924
Neoadjuvant therapy for melanoma: A critical appraisal
McKinley, S. K., & Brady, M. S. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27089
Carr, M. J., Ko, J., Swetter, S. M., Woodman, S. E., Sondak, V. K., Margolin, K. A., & Zager, J. S. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm110.pub2
Self-citationKretschmer, L., Bernhard, L., Leha, A., Kromer, C., Julius, K., Schön, M. P., & Schnabel, V. (2023) · International Journal of Cancer · doi:10.1002/ijc.34475
Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma
Bobak, K., Synoradzki, K. J., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_179-1
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2023) · doi:10.1158/0008-5472.c.6513799.v1
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2023) · doi:10.1158/0008-5472.c.6513799
Salama, A. K. S., Palta, M., Rushing, C. N., Selim, M. A., Linney, K. N., Czito, B. G., Yoo, D. S., Hanks, B. A., Beasley, G. M., Mosca, P. J., et al. (2023) · doi:10.1158/1078-0432.c.6530004
Marie, P. K., Haymaker, C., Parra, E. R., Kim, Y. U., Lazcano, R., Gite, S., Lorenzini, D., Wistuba, I. I., Tidwell, R. S. S., Song, X., et al. (2023) · doi:10.1158/1078-0432.c.6530172
Krijgsman, O., Kemper, K., Boshuizen, J., Vredevoogd, D. W., Rozeman, E. A., Molero, S. I., de Bruijn, B., Cornelissen‐Steijger, P., Shahrabi, A., Velasco‐Herrera, M. D. C., et al. (2023) · doi:10.1158/1078-0432.c.6530507
Data from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Najjar, Y. G., McCurry, D., Huang, L., Lin, Y., Zang, Y., Davar, D., Karunamurthy, A. D., Drabick, J. J., Neves, R. I., Butterfield, L. H., et al. (2023) · doi:10.1158/1078-0432.c.6530735
Krijgsman, O., Kemper, K., Boshuizen, J., Vredevoogd, D. W., Rozeman, E. A., Molero, S. I., de Bruijn, B., Cornelissen‐Steijger, P., Shahrabi, A., Velasco‐Herrera, M. D. C., et al. (2023) · doi:10.1158/1078-0432.c.6530507.v1
Salama, A. K. S., Palta, M., Rushing, C. N., Selim, M. A., Linney, K. N., Czito, B. G., Yoo, D. S., Hanks, B. A., Beasley, G. M., Mosca, P. J., et al. (2023) · doi:10.1158/1078-0432.c.6530004.v1
Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Grossmann, K. F., Othus, M. K. D., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T., Khushalani, N. I., Cohen, J. V., et al. (2023) · doi:10.1158/2159-8290.c.6549583.v1
Self-citationData from A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · doi:10.1158/2159-8290.c.6602824.v1
Data from A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · doi:10.1158/2159-8290.c.6602824
Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment
Lee, R. Y., Lau, M. C., Goh, D. L. M., Wee, F. Y. T., Lim, J. C. T., & YEONG, J. P. S. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_96-1 · Cited by 1
Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment
Lee, R. Y., Lau, M. C., Goh, D. L. M., Wee, F. Y. T., Lim, J. C. T., & YEONG, J. P. S. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_96-2
Liu, D., Xu, M., Xing, D., Ma, Y., & Shi, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2946391/v1
Top Melanoma Articles from 2021 to Inform Your Cancer Practice
Gershenwald, J. E. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13853-1
Self-citationNeoadjuvante Therapie des Melanoms
Fuchs, L., Gesierich, A., Schummer, P., & Schilling, B. (2024) · best practice onkologie · doi:10.1007/s11654-023-00546-0
Neoadjuvant therapy for resectable melanoma
Sharon, C. E., & Karakousis, G. C. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10263-1
Immunotherapy: Neoadjuvant and/or adjuvant? Literature review
Falaleeva, N. A., Bykova, E. A., Grivtsova, L. Y., Белохвостова, А. С., Danilenko, A. A., Сергеевна, П. И., Шегай, П. В., Иванов, С. А., & Каприн, А. Д. (2023) · Practical oncology · doi:10.31917/2404337
伊, 雯. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142567
Neoadjuvante Therapie des Melanoms
Fuchs, L., Gesierich, A., Schummer, P., & Schilling, B. (2024) · Die Onkologie · doi:10.1007/s00761-024-01506-1
Clinical insights into the efficacy of immune checkpoint inhibitors in patients with cancer
de Ruijter, L. K. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.952617592
Long, F., Lin, Z. X., Li, L., Ma, M., Lu, Z., Liang, J., Li, X., & Lin, C. (2021) · Figshare · doi:10.6084/m9.figshare.13710830
Long, F., Lin, Z. X., Li, L., Ma, M., Lu, Z., Liang, J., Li, X., & Lin, C. (2021) · Figshare · doi:10.6084/m9.figshare.13710824
Long, F., Lin, Z., Li, L., Ma, M., Lu, Z., Liang, J., Li, X., & Lin, C. (2021) · Figshare · doi:10.6084/m9.figshare.13710827
Long, F., Lin, Z. X., Li, L., Ma, M., Lu, Z., Liang, J., Li, X., & Lin, C. (2021) · Figshare · doi:10.6084/m9.figshare.13710836
Li, X., Xiang, Y., Zhen, Y.-H., & Yu, Y. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2258-8565
Immune Checkpoint Blockade in Melanoma – Earlier is Better?
Urbonas, V., Dulskas, A., Baltruškevičienė, E., & Dabkevičienė, D. (2024) · Acta medica Lituanica · doi:10.15388/amed.2024.31.1.16
Operables Melanom: Neoadjuvante Immuntherapie – eine vielversprechende Option
Gellrich, F. F. (2024) · Trillium Krebsmedizin · doi:10.47184/tk.2024.03.3
The emergence of neoadjuvant immune‐ over BRAF therapy in melanoma
Rozeman, E. A., & Luke, J. J. (2024) · Cancer · doi:10.1002/cncr.35490
Gholinezhad, M., Sartipi, B., & Shotorbani, B. S. (2023) · Biomedical Research Bulletin · doi:10.34172/biomedrb.2023.25
Evolution of Melanoma and Non-Melanoma Skin Cancer Management
Ch’ng, S., & Jeong, Y. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-57132-9_24
CD4 + Foxp3E2 + regulatory T cell frequency predicts breast cancer prognosis and recurrencePreprint
Fusco, C., Rella, F. D., Liotti, A., Colamatteo, A., Ferrara, A. L., Gigantino, V., Collina, F., Esposito, E., Donzelli, I., Porcellini, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.04.611142
Dheer, A., Tortorello, G. N., Shafique, N., Farooq, M. S., Mitchell, T. C., Xu, X., Miura, J. T., & Karakousis, G. C. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27933
Li, L., Wu, Z., Cao, R., & Yang, F. (2024) · International Conference on Biomedicine and Intelligent Technology (ICBIT) · doi:10.1145/3700486.3700517
Role of Surgery for Metastatic Melanoma in the Era of Checkpoint Blockade
Padmanaban, V., & Contreras, C. M. (2025) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.11.007
Seldomridge, A. N., Weiser, R., & Holder, A. M. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.01.003
Neoadjuvante Therapie des Melanoms
Mengoni, M., Gaffal, E., & Braun, A. D. (2025) · Die Dermatologie · doi:10.1007/s00105-025-05507-y
Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis
Wohlfeil, S. A., Weller, C., Dietsch, B., Agardy, D. A., Boschert, T., Vormehr, S. A., Dormann, C., Straub, N., Häfele, V., Platten, M., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217950 · Cited by 1
Cronin, C., Martin, F. T., Martin-Smith, J. D., Ajmal, N., Sullivan, P., O’Shea, A., Roche, M., Gulmann, C., ElBeltagi, N., O’Sullivan, B., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf265
Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma
Bobak, K., Synoradzki, K. J., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_179
Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment
Lee, R. Y., Lau, M. C., Goh, D. L. M., Wee, F. Y. T., Lim, J. C. T., & YEONG, J. P. S. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_96
Nicolini, F., Gaimari, A., Mazzotti, L., Lucia, A. D., Ghirelli, M., Ancarani, V., de Souza, P. B., Zurlo, M., Gazzola, L., Magnoni, C., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1636722
Rao, A., Mathavan, A., Mathavan, A., & Doonan, B. P. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1619248
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
